{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T23:50:44Z","timestamp":1785628244061,"version":"3.56.0"},"reference-count":36,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust Veterinary J"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Clinical scenario<\/jats:title>\n                    <jats:p>Canine osteoarthritis (OA) is a degenerative joint disease and is one of the most common chronic conditions in dogs and other species. The management of OA remains a longstanding focus in veterinary medicine. Traditionally, nonsteroidal anti\u2010inflammatory drugs (NSAIDs) have been the first\u2010line treatment option for canine OA. Recently, bedinvetmab, a canine\u2010specific monoclonal antibody (mAb) targeting the nerve growth factor (NGF), has been added as a pain management option for canine OA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical question<\/jats:title>\n                    <jats:p>Is monthly bedinvetmab injection safe in dogs over 12\u2009months old with OA compared with other interventions?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary of key findings<\/jats:title>\n                    <jats:p>Four articles met the inclusion criteria of a structured literature search and investigated adverse events (AEs) associated with bedinvetmab. Two studies investigated a 3\u2010month treatment period and did not find an increase in AEs associated with bedinvetmab in comparison with the placebo control group. The third study compared the safety of bedinvetmab to meloxicam in a 2\u2010month treatment period, where bedinvetmab was found to have fewer associated AEs. The fourth study conducted a disproportionality analysis, and the musculoskeletal AEs were reported significantly more frequently in bedinvetmab\u2010treated dogs than other traditional therapeutics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary of appraisal<\/jats:title>\n                    <jats:p>There is conflicting evidence regarding the safety of bedinvetmab, though stronger evidence supported the safety of bedinvetmab when administered for under 3\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Future research<\/jats:title>\n                    <jats:p>Future research should investigate the long\u2010term safety of bedinvetmab and incorporate radiographic imaging pre\u2010 and post\u2010treatment to monitor unusual joint changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/avj.70088","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:22:34Z","timestamp":1777994554000},"page":"549-556","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody"],"prefix":"10.1111","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6233-5466","authenticated-orcid":false,"given":"X","family":"Yang","sequence":"first","affiliation":[{"name":"School of Veterinary Science University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Macarthur","sequence":"additional","affiliation":[{"name":"School of Veterinary Science University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2021.110252"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2020.00220"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090501"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52324-9"},{"key":"e_1_2_9_6_1","unstructured":"Animal Medicines Australia.Pets in Australia: a national survey of pets and people [Internet]. Available from:https:\/\/animalmedicinesaustralia.org.au\/wp\u2010content\/uploads\/2025\/09\/SNR\u20102403006\u2010Pet\u2010Ownership\u2010Study\u20102025\u2010Designed_F3.pdf. Accessed 1 August 2025."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-020-02404-5"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2025.1565922"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2024.1374858"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.102435"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2002.tb00059.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12185"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746-6148-9-226"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.104590"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.12.6412"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","unstructured":"IsolaM FerrariV MioloAet al.Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteoarthritis.2011;24(4):279\u2013284.","DOI":"10.3415\/VCOT-10-04-0051"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2025.1558222"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00528-4"},{"key":"e_1_2_9_19_1","unstructured":"U.S. Food and Drug Administration.FDA notifies veterinarians about adverse events reported in dogs treated with Librela (bedinvetmab injection). Available at:https:\/\/www.fda.gov\/animal-veterinary\/product-safety-information\/dear-veterinarian-letter-notifying-veterinarians-about-adverse-events-reported-dogs-treated-librela. Accessed 25 September 2025."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaa.2021.08.001"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaa.2023.06.003"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2025.1502218"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2025.1581490"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2021.105733"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318219c171"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-07-02589.2000"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1701054114"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.160114"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2017.4108"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78983-y"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2025.1649240"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1573353"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.24.10.0665"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2023.08.010"},{"issue":"11","key":"e_1_2_9_35_1","first-page":"721","article-title":"La coxarthrose destructrice rapide [Rapidly destructive coxarthrosis]","volume":"37","author":"Lequesne M","year":"1970","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006395"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaa.2025.03.001"}],"container-title":["Australian Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/avj.70088","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/avj.70088","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/avj.70088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T23:30:57Z","timestamp":1785627057000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/avj.70088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/avj.70088"],"URL":"https:\/\/doi.org\/10.1111\/avj.70088","archive":["Portico"],"relation":{},"ISSN":["0005-0423","1751-0813"],"issn-type":[{"value":"0005-0423","type":"print"},{"value":"1751-0813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"2025-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}